



UNIVERSITY OF
LIVERPOOL



CELT

Community of Practice for Long-Acting Therapeutics for Maternal & Paediatric Health - First Meeting

**Rachel Daley
&
Adeniyi Olagunju**

Agenda

Time	Topic	Speaker
12 - 12.05pm	Introductions	Dr Olagunju & Rachel
12.05 – 12.30pm	CoP Objectives & Terms of Reference	All to review
12.30 – 12.45pm	Key Themes to explore	All to review & prioritise
12.45- 1.15pm	Rapid Insights Session to co-create the topics and format of our first in-person meeting 13 th July 2025.	Rachel to lead, all to participate
1.15- 1.30pm	Wrap up and close	Rachel and Dr Olagunju



UNIVERSITY OF
LIVERPOOL



CELT

Introductions


5 mins



CoP Objectives and Terms of Reference

25 mins

- CoP Objectives – 5 mins
- Terms of Reference 20 mins



Objectives

1. Collaboration
2. Share knowledge
3. Drive Innovation
4. Enhance access and equity
5. Improve patient outcomes



Interactive session

By the end of this part we hope to have:

- Agreement on **Purpose & Scope** of the CoP
- Prioritisation of Objectives
- Agreement on Membership, Roles, and Governance.
- Agreement on Code of Conduct principles.

Terms of Reference

Purpose

Purpose:

Significant gaps currently exist in the development of new medicines for women of child-bearing age and children, compared with the general adult population. This gap could expand further with new treatment modalities like LA therapeutics.

For instance, there is currently no guidance on possible changes in drug exposure from LA therapeutics due to the physiological changes associated with pregnancy.

Additionally, the extent of breastfed infant exposure through breastmilk is largely unknown. The dynamic nature of paediatric physiology has implications for transferability of adult-appropriate LA technologies to paediatric use.

Scope

Scope:

The overarching aim is to catalyse the development and availability of LA therapeutics of value for women of child-bearing age and children, in low- and middle-income countries.

This will be achieved through the following specific objectives:

1. Engaging relevant stakeholders in academia, clinical practice, pharmaceutical industry, regulators, women and patient groups;
2. Synthesise evidence-based perspectives on best practices for LA therapeutics;
3. Disseminate outputs from CoP for uptake by the wider community.

Outcomes

1. Publication of white papers and journal articles;
2. Growth in website traffic to assess usage of published resources;
3. Linkage with initiatives and other stakeholders.

Impact

1. Uptake of recommendations;
2. New targeted funding opportunities ;
3. New trials of in women (perinatal) & paediatrics;
4. New studies addressing key questions for women & paediatrics in LMICs.

Sustainability

Web resources on CELT website (liv.ac.uk/celt).

Membership

The CoP is open to individuals and organisations from the following stakeholder groups:

- Academia
- Industry
- NGOs and community organisations
- Patient groups
- Non-profits
- Regulatory bodies

Members agree to contribute actively, share expertise, and engage in CoP activities.

Roles and Responsibilities

- **CoP Members:** Participate in discussions, share insights, attend events, and collaborate on projects.
- **CoP Leadership:** Provide strategic guidance, ensure alignment with goals, and foster engagement.
- **Secretariat/Coordination:** Support operational aspects, manage communications, and facilitate activities.

Governance

The CoP will operate under a light-touch governance model, with:

- A Steering Committee to oversee strategic direction
- Working groups and task forces to focus on specific initiatives or projects

Meetings and Communication

Meeting dates for 2025/6 as follows:

First virtual 'Full CoP' meeting: Thursday 23rd January 12.30-2pm (GMT)

1st webinar: Wednesday 19th March (time TBC)

2nd webinar: Tuesday 22nd April (time TBC)

3rd webinar: Wednesday 4th June (time TBC)

In-person Full-Day 'Full CoP' and workshop, Liverpool (online option available too) –
Wednesday 16th July

4th webinar: Thursday 11th September (time TBC)

5th webinar: Wednesday 22nd October (time TBC)

6th webinar: Tuesday 9th December (time TBC)

3rd 'Full CoP' meeting: Thursday 15th January 2026

Code of Conduct

1. Promote and protect the interests of patients and carers as a priority
2. Communicate appropriately and effectively
3. Work within the limits of your knowledge and skills
4. Delegate appropriately
5. Respect confidentiality
6. Manage risk
7. Report concerns about safety
8. Be open when things go wrong
9. Be honest and trustworthy
10. Keep records of your work

Key Themes

Theme 1: Dynamic paediatric and maternal physiology in long-acting therapeutics development.

Theme 2: Formulation design, technology, and innovation.


Theme 3: Long-acting therapeutic accessibility and implementation in low- and middle-income countries.

Theme 4: Stakeholder engagement and community participation.

Theme 5: Policy advocacy & dissemination

Theme 6: Broader health system & ethical considerations

Key Themes




Rapid Insights Session

About this session:




Rapid insight events use a simple and interactive structure to gain insights from groups of stakeholders in a brief digital session.



We hope you will be able to share as much as possible with us in this session, to work towards co-design of our CoP webinar and workshop activities.




They are designed as a fast-paced and engaging way to encourage large amounts of information sharing in a short space of time.



We will offer alternative methods of contribution should you wish to reflect and share further thoughts. If you would like to participate more deeply, just let Rachel know in the feedback survey.

How does a rapid insights session work?



Inclusion and Accessibility:

While this session is aimed at capturing your thoughts and reflections to questions “in the moment” we also appreciate different styles of thinking and communication, so please also consider the following:

- We will provide you with a link at the end of the session for any thoughts that “bubble up” over the next few days.
- We also welcome any and all feedback you have about this process and your lived experience in whatever form suits you best. You can send an email to rachel.daley@liverpool.ac.uk at any time to connect.

Identifying perspectives

For each response you enter, we ask that you preface your ideas by indicating the stakeholder group/perspective you are coming from, using the following identifiers in the chat:

@regulator

@academic

@healthcareprovider

@NGO

@patient

etc

Ready to try it?



Thinking time

Theme 1: Dynamic paediatric and maternal physiology in long-acting therapeutics development.

Biggest Challenges?
Biggest Opportunities?

Feedback time

Please tag your responses:

@regulator @academic
@healthcareprovider
@NGO @patient etc

Thinking time

Theme 2: Formulation design,
technology, and innovation.

Biggest Challenges?
Biggest Opportunities?

Feedback time

Please tag your responses:

@regulator @academic
@healthcareprovider
@NGO @patient etc

Thinking time

Theme 3: Long-acting therapeutic accessibility and implementation in low- and middle-income countries.

**Biggest Challenges?
Biggest Opportunities?**

Feedback time

Please tag your responses:

@regulator @academic
@healthcareprovider
@NGO @patient etc

Thinking time

Theme 4: Stakeholder engagement and community participation.

**Biggest Challenges?
Biggest Opportunities?**

Feedback time

Please tag your responses:

@regulator @academic
@healthcareprovider
@NGO @patient etc

Thinking time

Theme 5: Policy advocacy & dissemination.

**Biggest Challenges?
Biggest Opportunities?**

Feedback time

Please tag your responses:

@regulator @academic
@healthcareprovider
@NGO @patient etc

Thinking time

**Theme 6: Broader health system
& ethical considerations.**


**Biggest Challenges?
Biggest Opportunities?**

Feedback time

Please tag your responses:

@regulator @academic
@healthcareprovider
@NGO @patient etc

Wrap-up and close



Thank You!



UNIVERSITY OF
LIVERPOOL



CELT